Chemours Opens Battery Innovation Center in US

US chemical company Chemours has opened its Chemours Battery Innovation Center (CBIC), a laboratory facility located at the company’s Discovery Hub in Newark, Delaware, US. A multi-million-dollar investment, the CBIC supports the testing and scaling of next generation battery technologies, to enable more sustainable, cost-effective, energy-efficient, and high-performing batteries for hybrid and electric vehicles (EVs), Chemours said.

“The Chemours Battery Innovation Center is a state-of-the-art lab and investment in the long-term potential of improving the sustainability footprint and performance of hybrid and electric vehicle batteries. We are committed to supporting the electrification of the automotive industry through collaboration and putting our team’s deep technical expertise to work,” said Denise Dignam, president and CEO at Chemours.

The CBIC aims to leverage Chemours’ application development expertise to drive innovation in partnership with customers to scale production of more sustainable, high-performance lithium-ion batteries (LiBs). The facility will serve as a technical support lab for partners and customers to collaborate with the company’s engineers to iterate, pilot, and adopt novel approaches to fabricating cost-effective LiBs.

“Electric vehicles are an essential part of the clean energy transition, and Chemours is dedicated to applying our advanced chemistry and material science knowledge to accelerate the electric future,” said Gerardo Familiar, president of Advanced Performance Materials at Chemours.

According to Chemours, the CBIC’s equipment and data analytics capabilities enable predictive modeling to help EV manufacturers adopt this novel battery manufacturing technology to contribute to better-performing EVs.

Chemours president & CEO Denise Dignam at the opening of the company’s...
Chemours president & CEO Denise Dignam at the opening of the company’s Battery Innovation Center. Source: Chemours

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.